研究论文
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger, Lyudmila A. Bazhenova, Corey Jay Langer, Ravi Salgia, Kathryn Ann Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss 等 16 位
Yale Cancer Center University of California San Diego University of Pennsylvania City of Hope
来源The Lancet Oncology
年份2016
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
59300
17
5918
19
20
21
22
23
24
25
26
关键指标
355
被引次数 · OpenAlex
37.76
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 0.1%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
27
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学Lung Cancer Treatments and Mutations
Lung Cancer Research Studies · Lung Cancer Diagnosis and Treatment
参考文献 27
Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion
被引 176Jürgen Hummel, Sue McKendrick, Charlie Brindley · Pharmaceutical Statistics · 2008
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
被引 1,503Alice Tsang Shaw, Dong-Wan Kim, Ranee Mehra · New England Journal of Medicine · 2014
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
被引 431Lynette Marie Sholl, Dara L. Aisner, Marileila Varella‐Garcia · Journal of Thoracic Oncology · 2015
此处列出前 3 条
引用本文 355
Lung cancer
被引 2,665Alesha A. Thai, Benjamin J. Solomon, Lecia Van Dam Sequist · The Lancet · 2021
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
被引 1,168Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari · The Lancet · 2017
Kinase drug discovery 20 years after imatinib: progress and future directions
被引 1,084Philip Cohen, Darren A.E. Cross, Pasi Antero Janne · Nature Reviews Drug Discovery · 2021
按被引量排序，此处列出前 3 条